Blood Markers and Asthma Severity in Children
Measures blood biomarker levels in children with asthma to study their link to severity.
Plain-language title generated from the registry record
Registry title: The Role of Biomarkers in the Occurrence and Development of Asthma
Key facts
- Where
- Chongqing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 4 and 12 years old?
Source: NCT05768399, who can take part
Where in China
- Shaoqing ZhangChongqing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Children's Hospital of Chongqing Medical University
- Trial code
- NCT05768399
- Record updated
- 7 July 2023
- Original description
To study the expression level of biomarkers such as GITRL in peripheral blood of children with asthma and analyze their correlation with the severity of asthma. To study the predictive value of biomarkers level for the occurrence and development of asthma. And to provide supplementary detection means and predictive indicators for the diagnosis of asthma and the severity of asthma.Read full original descriptionShow less
The Role of Biomarkers in the Occurrence and Development of Asthma
To study the expression level of biomarkers such as GITRL in peripheral blood of children with asthma and analyze their correlation with the severity of asthma. To study the predictive value of biomarkers level for the occurrence and development of asthma. And to provide supplementary detection means and predictive indicators for the diagnosis of asthma and the severity of asthma.
Inclusion: In line with the diagnostic criteria in the Guidelines for the Diagnosis and Prevention of Bronchial Asthma in Children (2016 Edition); Age: 4-12 years old for new diagnosis or recurrent episodes; Typical clinical manifestations and complete clinical data; Family members or guardians of children with informed research and signed consent; All healthy control subjects had no history of lung disease, allergic rhinitis or any other atopic disease.
Exclusion: Suffering from other respiratory diseases (such as bronchiectasis, allergic rhinitis, respiratory failure, tuberculosis, obstructive airway disease) or other inflammatory diseases; History of immunosuppressant or glucocorticoid use in the first 4 weeks; Suffering from other endocrine system and immune system diseases; Abnormal development of congenital airway and lung tissue; Incomplete clinical data or examinations.